Coagulation disorders and the risk of retinal vein occlusion.
نویسندگان
چکیده
Over the past years, there has been a dramatic increase in the number of identifiable causes of thrombophilia. However, to date, there are no large, prospective studies to assess an optimal, cost-effective approach with regard to screening and case finding for thrombophilic risk factors in patients presenting with retinal vessel occlusion. Two hundred twenty-eight patients with retinal vein occlusion (RVO) and 130 age-matched healthy controls were prospectively screened for thrombophilic risk factors. Both cohorts were divided into three subgroups, depending on the patients' age at the time of the RVO or a previous thromboembolic event. Patient age < or =45 years was associated with a high prevalence of coagulation disorders (p<0.0001). Among patients < or =45 years and >45 to < or =60 years, a family history of thromboembolism was strongly associated with the presence of thrombophilic disorders. The absence of cardiovascular risk factors was found to be a strong predictor for the presence of coagulation disorders in all patient groups (< or =45 years, p=0.003; >45 to < or =60 years, p=0.0008; >60 years, p=0.001). Multivariate analysis revealed the presence of resistance to activated protein C (p=0.014), antiphospholipid antibodies (p=0.022), and deficiency of the anticoagulant proteins (p=0.05) as independent risk factors for the development of RVO among patients < or =45 years. Our results indicate that thrombophilic disorders are associated with the development of retinal vein occlusion in patients < or =45 years by the time of the RVO or a previous thromboembolic event, in patients with a family history of thromboembolism, or in patients without cardiovascular risk factors.
منابع مشابه
Role of Transthoracic Echocardiography in the Evaluation of Patients with Retinal Vein Occlusion
Introduction: Retinal vein occlusion is a common vascular disorder disrupting vision. Two basic types of RVO are branch retinal vein occlusion and central retinal vein occlusion (CRVO). Retinal vein occlusion is a multifactor process including systemic illness and local retinal factors.RVO may be associated with atherosclerotic risk factors. We analyzed the role of 2 dimensional transthor...
متن کاملEvaluation of Optical Coherence Tomography Angiography Findings in Patients with Branch Retinal Vein Occlusion
Purpose: To analyze the correlation of optical coherence tomography angiography (OCTA) findings with visual acuity (VA) in patients with branch retinal vein occlusion (BRVO). Methods: This cross-sectional study was performed on 20 eyes of 20 patients with unilateral BRVO involving the macula referred to the ophthalmology clinic of Rassoul Akram Hospital. OCTA imaging was conducted for all patie...
متن کاملBaseline subfoveal choroidal thickness as an indicator for bevacizumab outcomes in central retinal vein occlusion
Background: Retinal vein occlusions are one of the most common form of retinal vascular disorders and could lead to vision loss due to macular edema, macular ischemia and sequelae from neovascularization. Anti-venous endothelial growth factor (anti-VEGF) treatment is the choice strategy of treatment for patients with macular edema secondary to central retinal vein occlusion (CRVO). There is an ...
متن کاملSulfur Mustard Exposure and Non-Ischemic Central Retinal Vein Occlusion
A 41-year-old man was referred with a complaint of visual loss in his left eye and his best corrected visual acuity was 20/80. Slit lamp examination showed arborizing conjunctival vessels and dry eye. Fundus examination and fluorescein angiography revealed a non-ischemic central retinal vein occlusion. Cardiovascular, rheumatologic, and hematologic work up showed no abnormal findings. An ascert...
متن کاملOutcomes of Intravitreal bevacizumab in patients with acute branch retinal vein occlusion
Introduction: The study aimed to evaluate the long-term effects of intravitreal bevacizumab on macular edema and visual acuity in patients with Acute branch Retinal Vein Occlusion (BRVO) that had not received any treatment. Methods: 22 patients in first week of BRVO onset that was diagnosed with flurcein angiography were treated with intravitreal injection of 1.25 mg bevacizumab. Macular thicke...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Thrombosis and haemostasis
دوره 103 2 شماره
صفحات -
تاریخ انتشار 2010